GlassScriptPhysician profile
Karla D Hostetler
NPI 1669436366
$2,330.53
in general payments reported to CMS, 2019-2025
29 companies · $618 in 2025
The $618 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $432 · 2022: $507 · 2023: $530 · 2024: $244 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $415.03 | 2021-2025 | |
| Lilly USA, LLC | $251.95 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $251.85 | 2021-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $232.28 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $163.39 | 2021-2025 | |
| Glaxosmithkline, LLC. | $154.44 | 2021-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Novo Nordisk INC | $130.29 | 2021-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $125.28 | 2021-2023 | Xarelto |
| Medtronic, INC. | $96.18 | 2025 | Intellis Adaptivestim |
| Abbott Laboratories | $80.34 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $50.66 | 2023-2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.49 | 2021-2022 | |
| Corcept Therapeutics | $40.22 | 2024 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $31.17 | 2022 | |
| Merck Sharp & Dohme LLC | $31.03 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $29.29 | 2021-2022 | |
| Lundbeck LLC | $26.33 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $24.50 | 2025 | Rexulti |
| Insulet Corporation | $21.57 | 2025 | Omnipod |
| Apria Healthcare LLC | $15.52 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.19 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $15.16 | 2024 | Quviviq |
| Sanofi Pasteur INC. | $13.72 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.45 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.98 | 2023 | Xifaxan |
| Collegium Pharmaceutical, INC. | $12.71 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.21 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.14 | 2021 | |
| Mylan Specialty L.P. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Hostetler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.